CEL-SCI FDA OK for Study of Multikine in Head & Neck Cancer

 

• Critical milestone achieved—the FDA accepted CEL-SCI’s selection criteria defining the Multikine target population before surgery

• Selected patient population had 73% survival with Multikine vs. 45% without Multikine based on analysis of completed 928-patient Phase 3 randomized controlled trial

• 212-patient confirmatory study is de-risked, backed by robust efficacy and safety data from completed Phase 3 trial, the largest in advanced primary head and neck cancer

• View CEL-SCI’s comprehensive report regarding the FDA’s go-ahead and the Company’s value proposition for investors here: https://cel-sci.com/wp-content/uploads/2024/05/CEL_SCI-Report-on-FDA-Path-Forward-May-2024-FINAL.pdf

https://finance.yahoo.com/news/cel-sci-receives-fda-ahead-130000511.html